More Videos
- At The End Of The Day: Dendreon
- Celgene's Success Story
- Amylin's Byetta Battle
- Orexigen And Its Obesity Bets
- Medivation's Presentation
- Biotech Bonanza At Industry Conference
- Pfizer Finding Innovation At Medivation
- No Vindication For Vytorin; Victory for Sciele
- Hurricane Lurking For Merck & Schering-Plough?
- Merck's Charm Offensive
- Chad Ocho Cinco Jerseys Will Be Available
- Nothing About New Cars Excites You? Are You Kidding?
- PlayStation, Xbox And Post That Launched A "Thousand" Emails
- Jobs Numbers: Breakdown by Sector
- Sudden Death: ValueClick and More
- Wells Fargo Responds to Bill Gross Comments
- Sell Block: Cramer Condemns Hovnanian
- Lightning Round OT: Corning, Giant Interactive and More
- Lightning Round: FedEx, Deere, Dow Chemical and More
- Rising Dollar to Curb Exports: Feldstein
- Nokia Shares Fall on Third Quarter Warning
- Unemployment Jumps to 6.1%, Fueling Recession Fears
- Europe Slowdown Worse than US: Goldman
- How China's Bet on US Paper Went Wrong
- Altria in Talks to Buy UST for $10 Billion
- Euro Stocks Fall on Growth Fears
- Dell Plans to Sell Computer Factories: Report
- Euro Zone Collateral Rules Toughen to Fight Abuse
 |
Fourth of July fireworks |
Taxus is the name of Boston Scientific's [BSX
Loading...
()
] drug-coated stent, a tiny wire mesh cylinder that props open clogged arteries. This isn't all that surprising given the fact that Medtronic [MDT
Loading...
()
]recently entered the drug-coated stent market, busting up the duopoly of BSX and Johnson & Johnson[JNJ
Loading...
()
].
And any day now, there could be a fourth player. Some analysts still expect Abbott[ABT
Loading...
()
] to win Food and Drug Administration approval of its drug-coated stent Xience by the end of this month. But at least a couple of them, including FBR's Warren, now believe approval could come later rather than sooner. The analyst quotes an interventional cardiologist (the docs who put in stents) who says ABT's sales reps are telling him (the doc) that Xience will be launched in the fourth quarter.
JPMorgan's medical device guy Mike Weinstein emailed me to say that Abbott is apparently telling him to continue to look for approval here in Q2. Under the odd terms of BSX's acquisition of Guidant--it had to sell pieces of it to ABT--Boston Scientific would get to sell the Xience stent, but using the brand name Promus. Most analysts think Xience will quickly become the stent of choice because tests have shown it may have a lower rate of blood clots forming down the road and doctors think it's easier to put in.
Warren says his expert who works here in the New York area indicated that drug-coated stent prices have fallen 21 percent over the past year to the $1,100 BSX is charging in its bundling deal regardless of how many stents a cath lab (the highly profitable unit of a hospital where stent procedures are done) might buy. FBR makes a market in BSX.
I've left a landline and mobile voicemail and sent an email to BSX's main spokesman to try to confirm the FBR report. Usually I get a quick reply, but it's vacation season. And in the past the company hasn't commented outside of an earnings press release or conference call on current pricing.
UPDATE: So, I did hear back via email from BSX spokesman Paul Donovan who, as I suspected he would, wrote, "We typically don't comment on price beyond list price."
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes